close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

In SAD Patients, Autumn Antidepressants Can Prevent Winter Depression

In SAD Patients, Autumn Antidepressants Can Prevent Winter Depression

Biological Psychiatry publishes novel approach to Winter Blues

NEW YORK, November 7, 2005 - For patients with seasonal affective disorder (SAD), starting treatment with an antidepressant medication during the fall can reduce the risk of developing depression throughout the fall and winter months, reports a study in the Oct. 15 issue of Biological Psychiatry, official journal of the Society of Biological Psychiatry, published by Elsevier, a world-leading scientific and medical publisher.

"These are the first systematic studies that indicate that SAD can actually be prevented in some patients by starting antidepressants early in the season, before the development of symptoms," comments Norman E. Rosenthal, M.D., Clinical Professor of Psychiatry, Georgetown Medical School, and one of the authors of the paper and leader of the research team that first described SAD over 20 years ago.

Dr. Rosenthal and colleagues performed a study with more than 1,000 patients with SAD from the northern United States and Canada. The patients, 70% of whom were women, reported an average of 13 previous episodes of fall-winter depression. Notwithstanding this long history, almost 60% of patients had received no previous treatment for their episodes of depression.

The researchers attempted to prevent the development of fall-winter depression though pre-emptive treatment with the antidepressant bupropion extended release tablets. One group of patients was randomly assigned to start treatment with bupropion-XL during the fall, while they were still well. Patients in the other group received an inactive placebo. The two groups were then followed over the winter season.

The relapse rate was 16% for patients taking bupropion extended release compared with 28% for those taking placebo. Early antidepressant treatment reduced the overall risk of fall-winter depression by about 44%. The antidepressant medication was generally well tolerated. When the patients stopped taking bupropion extended release in the spring, there was no increase in the depression relapse rate compared with the placebo group.

Patients with SAD have episodes of depression occurring in the fall and winter months. Although the cause is unknown, SAD appears related to reduced exposure to sunlight during the fall and winter in northern latitudes-genetic factors likely play a role as well. As in the current study, many patients with SAD are not treated with antidepressant medications, despite having many previous episodes of seasonal depression.

Starting antidepressant treatment in the fall offers a new option for reducing the rate of fall-winter depression in patients with SAD, the results suggest. "It is a highly novel approach to start treatment before the development of a major depressive disorder," says Dr. Rosenthal, author of the newly revised Winter Blues: Seasonal Affective Disorder: What It Is and How to Overcome It (Guilford Publications, 2005).

"The strategy makes sense when dealing with a condition where the pattern of relapse is somewhat predictable and the symptoms being prevented can be highly distressing and debilitating," comments Dr. Rosenthal. "In my opinion, the treatment used in the present study offers a valuable new option for those afflicted year after year by winter depression."

About the Society of Biological Psychiatry

The Society of Biological Psychiatry was founded in 1945 to emphasize the medical and scientific study and treatment of mental disorders. Its continuing purpose is to foster scientific research and education and to raise the level of knowledge and comprehension in the field of psychiatry. To achieve its purpose, the Society sponsors an annual meeting, grants awards to distinguished clinical and basic research workers, and publishes the journal Biological Psychiatry. Visit the Society's website at www.sobp.org.

Source: Elsevier

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...